Elaheh Binabaji

Title: Elaheh Binabaji: Innovator in PCSK9-Binding Polypeptides

Introduction

Elaheh Binabaji is a prominent inventor based in Los Angeles, CA. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of formulations for PCSK9-binding polypeptides. With a total of 3 patents to her name, her work is paving the way for advancements in treating cholesterol-related conditions.

Latest Patents

One of her latest patents focuses on low-viscosity, high concentration evolocumab formulations and methods of making the same. This patent provides formulations of PCSK9-binding polypeptides, such as evolocumab, that include N-acetyl arginine. These formulations exhibit reduced viscosities compared to those lacking N-acetyl arginine. Additionally, the methods of formulating these compositions are advantageous as they conserve certain components. Such formulations can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.

Career Highlights

Elaheh Binabaji is currently employed at Amgen Inc., a leading biotechnology company. Her work at Amgen has allowed her to focus on innovative solutions in the biopharmaceutical sector. Her expertise in the formulation of therapeutic agents has positioned her as a key player in her field.

Collaborations

Throughout her career, Elaheh has collaborated with notable colleagues, including Chio Mui Chan and Christopher James Sloey. These collaborations have further enhanced her research and development efforts in the biopharmaceutical industry.

Conclusion

Elaheh Binabaji's contributions to the field of biopharmaceuticals, particularly through her innovative formulations, are noteworthy. Her work continues to impact the treatment of PCSK9-related conditions, showcasing her dedication to advancing medical science.